Nivolumab-related severe thrombocytopenia in a patient with relapsed lung adenocarcinoma: a case report and review of the literature

Nivolumab-related severe thrombocytopenia in a patient with relapsed lung adenocarcinoma: a case report and review of the literature

Abstract Background Immune checkpoint inhibitor therapy has changed the standard drug therapy for relapsed or advanced non-small cell lung cancer; its efficacy is well-recognized by pulmonary physicians, oncologists, and thoracic surgeons. Nivolumab, one of the anti-programmed cell death 1 antibodie...

Full description

Bibliographic Details
Main Authors: Takeo Hasegawa, Yuki Ozaki, Takuya Inoue, Yuzuru Watanabe, Mitsuro Fukuhara, Takumi Yamaura, Satoshi Muto, Naoyuki Okabe, Mitsunori Higuchi, Yutaka Shio, Hiroyuki Suzuki
Format: Article
Language:English
Published: BMC 2019-10-01
Series:Journal of Medical Case Reports
Subjects:
Nivolumab
Immune checkpoint inhibitor
Non-small cell lung cancer
Immune-related thrombocytopenia
Online Access:http://link.springer.com/article/10.1186/s13256-019-2245-y

Internet

http://link.springer.com/article/10.1186/s13256-019-2245-y

Similar Items